<DOC>
	<DOCNO>NCT00453089</DOCNO>
	<brief_summary>To conduct prospective , randomize , blind , placebo control , dose escalation clinical trial 4 cohort 10 postmenopausal woman ( total N=40 ) age 45 65 year least one menopausal vaginal symptom , vaginal pH &gt; 5.0 &gt; 20 % parabasal vaginal epithelial cell .</brief_summary>
	<brief_title>VG101 Phase I/II Treat Vulvar Vaginal Atrophy Post-Menopausal Women</brief_title>
	<detailed_description>Primary Aims : 1. optimal dose VG101 base high 4 propose dose level associate unacceptable toxicity 12 week treatment . Toxicity base National Cancer Institute ( NCI ) Common Toxicity Criteria Adverse Events ( CTCAE ) , version 3 . Unacceptable toxicity define occurrence Grade 3 , 4 , 5 toxicity possibly probably associate study drug unacceptable toxicity determine Data Safety Monitoring Board . 2 . Specific potential adverse effect VG101 Secondary Aims : 1. preliminary efficacy VG101 : - relieve vulvar and/or vaginal dryness , - relieve vulvar and/or vaginal irritation - relieve vulvar and/or vaginal itch - relieve vulvar and/or vaginal discharge - relieve dyspareunia - improve sexual function - relieve dysuria - reduce frequency urinary incontinence - improve quality life - improve physical examination assessment vaginal atrophy - reduce vaginal fluid pH - improve proportion superficial vaginal epithelial cell 2. participant adherence VG101 administration</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<criteria>1 . Women age 45 65 2 . Postmenopausal document : ( ) least one year amenorrhea ; ( b ) 6 12 month amenorrhea serum FSH &gt; 40 IU/ml ; ( c ) 6 week postsurgical bilateral oophorectomy without hysterectomy , ( ) hysterectomy serum FSH level &gt; 40 IU/ml . 3 . Selfreport least one moderate severe symptom vulvar vaginal atrophy follow list : Vaginal dryness ( none , mild , moderate severe ) Vaginal and/or vulvar discomfort ( none , mild , moderate , severe ) Vaginal and/or vulvar irritation ( none , mild , moderate , severe ) Vaginal itching ( none , mild , moderate , severe ) Vaginal pain associate sexual activity ( none , mild , moderate severe ) 4 . &lt; 5 % superficial cell vaginal cytologic smear . 5 . Vaginal pH &gt; 5.0 6 . Willing use intravaginal cream contain Chinese herbs treatment vaginal symptom . 7 . Provide informed consent . 1 . History breast , uterine ovarian cancer melanoma . 2 . Abnormal mammogram breast examination within last 9 month suggestive cancer . 3 . Abnormal Pap smear pelvic examination within last 9 month suggestive cancer . 4 . Any uterine vaginal bleeding within six month prior enrollment ( except follow screen Pap smear ) . 5 . Doublewall endometrial thickness exceed 5 mm measure transvaginal ultrasound . 6 . Pregnant lactating . 7 . Use vaginal moisturizer ( Replens , KY SilkE , Astroglide Silken Secret , Senselle ) within 30 day screen . 8 . Use oral , transdermal , vaginal , systemic estrogen estrogen/progestin product within 30 day screen . 9 . Use raloxifene , tamoxifen aromatase inhibitor within 12 week screen . 10 . Current urinary tract infection ( dipstick urinalysis positive leukocyte estrace , nitrate blood ) 11 . History cardiovascular disease . 12 . History venous thromboembolic disease . 13 . Use another investigational agent within 12 week screen . 14 . Any medical psychiatric condition , investigator 's opinion , would preclude participant complete questionnaire measure , adhere protocol complete trial , include limited English literacy , severe illness , plan move , substance abuse , significant psychiatric problem , dementia . 15 . No access telephone</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Chinese Herbs</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Vaginal Atrophy</keyword>
	<keyword>Vulvar Atrophy</keyword>
	<keyword>Symptoms</keyword>
	<keyword>Bionovo</keyword>
	<keyword>VG101</keyword>
</DOC>